Partnership on HIV patient genotyping:
This article was originally published in Clinica
Clinical Partners, the US's largest HIV managed care organisation with over 6000 HIV patients, has signed Visible Genetics, of Toronto, as the exclusive supplier of patient genotyping services for its clinical trials. The two companies are to investigate genotyping of HIV patients as a way of managing evolving HIV resistance to drug regimes.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.